Cargando…
Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is limited, and only a few cases have performed...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669433/ https://www.ncbi.nlm.nih.gov/pubmed/37998841 http://dx.doi.org/10.3390/antibiotics12111639 |
_version_ | 1785149231212789760 |
---|---|
author | Gallerani, Altea Gatti, Milo Bedini, Andrea Casolari, Stefania Orlando, Gabriella Puzzolante, Cinzia Franceschini, Erica Menozzi, Marianna Santoro, Antonella Barp, Nicole Volpi, Sara Soffritti, Alessandra Pea, Federico Mussini, Cristina Meschiari, Marianna |
author_facet | Gallerani, Altea Gatti, Milo Bedini, Andrea Casolari, Stefania Orlando, Gabriella Puzzolante, Cinzia Franceschini, Erica Menozzi, Marianna Santoro, Antonella Barp, Nicole Volpi, Sara Soffritti, Alessandra Pea, Federico Mussini, Cristina Meschiari, Marianna |
author_sort | Gallerani, Altea |
collection | PubMed |
description | Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is limited, and only a few cases have performed therapeutic drug monitoring (TDM) analysis to optimize dosage in suppressive treatments longer than 4 weeks. Our retrospective case series reports the use of dalbavancin in a small cohort of patients with cardiovascular prosthetic infections (cardiac implantable electronic device infections (CEDIs), prosthetic valve endocarditis (PVE), prosthetic vascular graft infections (PVGIs)) treated with dalbavancin as sequential therapy. From May 2019 to May 2023, 14 patients were included: eight cases of PVE (57.1%), seven cases of PVGI (50%), three cases of CEDI (21.4%), and four cases with overlap of infection sites (28.6%). The main pathogen was Staphylococcus aureus (35.7%). Prosthesis replacement was obtained in four patients (28.6%). The median time between symptom onset and the end of treatment was 15 weeks (IQR 7–53), with a median duration of dalbavancin therapy of 8 weeks (IQR 1 to 45 weeks) and 3.5 doses per patient. Among patients managed with TDM-guided strategy, dalbavancin infusion intervals ranged from 4 to 9 weeks. The median length of follow-up was 65 weeks (IQR 23 to 144 weeks). Clinical success was achieved in 10 cases (76.9%); all clinical failures occurred in patients with the implant retained. Among patients monitored by TDM, clinical success was 87.5% vs. 60% in patients treated without TDM. Because of pharmacokinetic individual variability, dalbavancin TDM-guided administration could improve clinical outcomes by individualizing dosing and selecting dosing intervals. This case series seems to suggest a promising role of long-term suppressive dalbavancin treatment for difficult-to-treat cardiovascular prosthesis infection, also with limited surgical indications. |
format | Online Article Text |
id | pubmed-10669433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106694332023-11-19 Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections Gallerani, Altea Gatti, Milo Bedini, Andrea Casolari, Stefania Orlando, Gabriella Puzzolante, Cinzia Franceschini, Erica Menozzi, Marianna Santoro, Antonella Barp, Nicole Volpi, Sara Soffritti, Alessandra Pea, Federico Mussini, Cristina Meschiari, Marianna Antibiotics (Basel) Article Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is limited, and only a few cases have performed therapeutic drug monitoring (TDM) analysis to optimize dosage in suppressive treatments longer than 4 weeks. Our retrospective case series reports the use of dalbavancin in a small cohort of patients with cardiovascular prosthetic infections (cardiac implantable electronic device infections (CEDIs), prosthetic valve endocarditis (PVE), prosthetic vascular graft infections (PVGIs)) treated with dalbavancin as sequential therapy. From May 2019 to May 2023, 14 patients were included: eight cases of PVE (57.1%), seven cases of PVGI (50%), three cases of CEDI (21.4%), and four cases with overlap of infection sites (28.6%). The main pathogen was Staphylococcus aureus (35.7%). Prosthesis replacement was obtained in four patients (28.6%). The median time between symptom onset and the end of treatment was 15 weeks (IQR 7–53), with a median duration of dalbavancin therapy of 8 weeks (IQR 1 to 45 weeks) and 3.5 doses per patient. Among patients managed with TDM-guided strategy, dalbavancin infusion intervals ranged from 4 to 9 weeks. The median length of follow-up was 65 weeks (IQR 23 to 144 weeks). Clinical success was achieved in 10 cases (76.9%); all clinical failures occurred in patients with the implant retained. Among patients monitored by TDM, clinical success was 87.5% vs. 60% in patients treated without TDM. Because of pharmacokinetic individual variability, dalbavancin TDM-guided administration could improve clinical outcomes by individualizing dosing and selecting dosing intervals. This case series seems to suggest a promising role of long-term suppressive dalbavancin treatment for difficult-to-treat cardiovascular prosthesis infection, also with limited surgical indications. MDPI 2023-11-19 /pmc/articles/PMC10669433/ /pubmed/37998841 http://dx.doi.org/10.3390/antibiotics12111639 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gallerani, Altea Gatti, Milo Bedini, Andrea Casolari, Stefania Orlando, Gabriella Puzzolante, Cinzia Franceschini, Erica Menozzi, Marianna Santoro, Antonella Barp, Nicole Volpi, Sara Soffritti, Alessandra Pea, Federico Mussini, Cristina Meschiari, Marianna Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections |
title | Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections |
title_full | Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections |
title_fullStr | Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections |
title_full_unstemmed | Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections |
title_short | Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections |
title_sort | long-term suppressive therapeutic-drug-monitoring-guided dalbavancin therapy for cardiovascular prosthetic infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669433/ https://www.ncbi.nlm.nih.gov/pubmed/37998841 http://dx.doi.org/10.3390/antibiotics12111639 |
work_keys_str_mv | AT galleranialtea longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT gattimilo longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT bediniandrea longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT casolaristefania longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT orlandogabriella longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT puzzolantecinzia longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT franceschinierica longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT menozzimarianna longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT santoroantonella longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT barpnicole longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT volpisara longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT soffrittialessandra longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT peafederico longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT mussinicristina longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections AT meschiarimarianna longtermsuppressivetherapeuticdrugmonitoringguideddalbavancintherapyforcardiovascularprostheticinfections |